T1395 Fermented Milk Containing the Probiotic Bifidobacterium Animalis, DN-173 010 (FM) Improves Abdominal Distension, Bloating and Transit in Irritable Bowel Syndrome with Constipation (IBS-C)

2008 ◽  
Vol 134 (4) ◽  
pp. A-546 ◽  
Author(s):  
Anurag Agrawal ◽  
Lesley A. Houghton ◽  
Julie Morris ◽  
Denis Guyonnet ◽  
Nathalie Goupil Feuillerat ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Distension ◽  
Fermented Milk ◽  
Bifidobacterium Animalis ◽  
Irritable Bowel

Constipation and recurrent abdominal distension in a 39-year-old woman with irritable bowel syndrome

Gut ◽  
2011 ◽  
Vol 61 (1) ◽  
pp. 42-42 ◽  
Author(s):  
Seth Sweetser ◽  
Archana S Rao ◽  
Lawrence A Szarka
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Distension ◽  
Irritable Bowel

scholarly journals Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Yu-xia Ma ◽  
Xiao Liu ◽  
Cun-zhi Liu ◽  
Lin-peng Wang ◽  
Gang Guo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Adverse Events ◽  
Abdominal Distension ◽  
Clinical Effects ◽  
End Of Treatment ◽  
Significant Difference ◽  
Irritable Bowel

Objective. To explore the efficacy of Herb-partitioned moxibustion in treating IBS-D patients.Method. 210 IBS-D patients were randomly assigned on a3:3:2basis to group HM, group FM, or group PB for 4-week treatment. The change of GSRS total score at weeks 4 and 8, the changes of GSRS specific scores, and adverse events were evaluated.Results. Patients in group HM and group FM had lower GSRS total score at week 4 (1.98±0.303,2.93±0.302versus3.73±0.449) and at week 8 (2.75±0.306,3.56±0.329versus4.39±2.48) as compared with patients’ score in group PB. However, there was no significant difference of GSRS total score between group HM and group FM. The effect of HM was significantly greater than that of orally taking PB in ameliorating the symptoms of rugitus (0.38 versus 0.59,P<0.05), abdominal pain (0.28 versus 0.57,P<0.01), abdominal distension (0.4 versus 0.7,P<0.01), and increased passage of stools (0.06 versus 0.25,P<0.01) at the end of treatment period. In the follow-up period, patients’ therapeutic effect in group HM remained greater than that in group FM (in abdominal pain, abdominal distension, and increased passage of stools) and that in group PB (in loose stools).Conclusions. HM appears to be a promising, efficacious, and well-tolerated treatment for patients with IBS-D.

Sign in / Sign up

Export Citation Format

Share Document